JP2008208114A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008208114A5 JP2008208114A5 JP2007327323A JP2007327323A JP2008208114A5 JP 2008208114 A5 JP2008208114 A5 JP 2008208114A5 JP 2007327323 A JP2007327323 A JP 2007327323A JP 2007327323 A JP2007327323 A JP 2007327323A JP 2008208114 A5 JP2008208114 A5 JP 2008208114A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- dementia
- disease
- episodes
- mood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012289 Dementia Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 230000004770 neurodegeneration Effects 0.000 claims 5
- 230000036651 mood Effects 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010026749 Mania Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000027099 Paranoid disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 229910052802 copper Inorganic materials 0.000 claims 2
- 239000010949 copper Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 241000218236 Cannabis Species 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 208000024791 Schizotypal Personality disease Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 229940025084 amphetamine Drugs 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000022257 bipolar II disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000003001 depressive effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 201000002545 drug psychosis Diseases 0.000 claims 1
- 230000001037 epileptic effect Effects 0.000 claims 1
- 239000000380 hallucinogen Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 208000024817 paranoid personality disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 1
- 229950010883 phencyclidine Drugs 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87126006P | 2006-12-21 | 2006-12-21 | |
| US60/871260 | 2006-12-21 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008208114A JP2008208114A (ja) | 2008-09-11 |
| JP2008208114A5 true JP2008208114A5 (enExample) | 2011-02-03 |
| JP5254602B2 JP5254602B2 (ja) | 2013-08-07 |
Family
ID=39321475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007327323A Expired - Fee Related JP5254602B2 (ja) | 2006-12-21 | 2007-12-19 | ２−（（４−（１−メチル−４−（ピリジン−４−イル）−１ｈ−ピラゾール−３−イル）フェノキシ）メチル）キノリンのコハク酸塩 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8283471B2 (enExample) |
| EP (1) | EP2125786B1 (enExample) |
| JP (1) | JP5254602B2 (enExample) |
| KR (2) | KR20090092338A (enExample) |
| CN (1) | CN101611029B (enExample) |
| AR (1) | AR064417A1 (enExample) |
| AT (1) | ATE502028T1 (enExample) |
| AU (1) | AU2007343135B2 (enExample) |
| BR (1) | BRPI0720936A2 (enExample) |
| CA (1) | CA2673435C (enExample) |
| CY (1) | CY1111919T1 (enExample) |
| DE (1) | DE602007013294D1 (enExample) |
| DK (1) | DK2125786T3 (enExample) |
| ES (1) | ES2360014T3 (enExample) |
| IL (1) | IL199389A (enExample) |
| MX (1) | MX2009006528A (enExample) |
| NZ (1) | NZ577716A (enExample) |
| PL (1) | PL2125786T3 (enExample) |
| PT (1) | PT2125786E (enExample) |
| RU (1) | RU2430918C2 (enExample) |
| SI (1) | SI2125786T1 (enExample) |
| TW (1) | TWI359660B (enExample) |
| WO (1) | WO2008084299A1 (enExample) |
| ZA (1) | ZA200904230B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| US20120214842A1 (en) * | 2011-02-18 | 2012-08-23 | Exonhit Therapeutics Sa | Methods for treating diseases of the retina |
| EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | benzothiophene derivative |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| KR102233916B1 (ko) * | 2019-05-28 | 2021-03-30 | 주식회사 엘지생활건강 | Pq1 숙신산을 포함하는 피부 보습, 주름 개선 및 탄력 증진용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4105551A1 (de) * | 1991-02-22 | 1992-08-27 | Bayer Ag | 2-substituierte chinoline, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| EA011451B1 (ru) * | 2001-02-12 | 2009-04-28 | Уайт | Новая соль сукцинат о-десметилвенлафаксина |
| IL161326A0 (en) * | 2001-11-29 | 2004-09-27 | Pfizer Prod Inc | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2 (11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| CN1608062A (zh) * | 2001-12-12 | 2005-04-20 | 辉瑞产品公司 | E－2－甲氧基－n－(3－{4－[3－甲基－4－(6－甲基－吡啶－3－基氧基) －苯氨基]－喹唑啉－6基}－烯丙基)－乙酰胺的盐，其制备和抗癌用途 |
| CA2536073A1 (en) * | 2003-08-18 | 2005-02-24 | H. Lundbeck A/S | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
| WO2006072828A2 (en) * | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| WO2006078825A2 (en) | 2005-01-21 | 2006-07-27 | Cabot Corporation | Processes for forming nanoparticles |
| AU2006329849A1 (en) * | 2005-12-16 | 2007-07-05 | Wyeth | Lyophilized compositions of a triazolopyrimidine compound |
-
2007
- 2007-12-03 CN CN200780051566.5A patent/CN101611029B/zh not_active Expired - Fee Related
- 2007-12-03 EP EP07858987A patent/EP2125786B1/en not_active Not-in-force
- 2007-12-03 AU AU2007343135A patent/AU2007343135B2/en not_active Ceased
- 2007-12-03 CA CA2673435A patent/CA2673435C/en not_active Expired - Fee Related
- 2007-12-03 SI SI200730561T patent/SI2125786T1/sl unknown
- 2007-12-03 PL PL07858987T patent/PL2125786T3/pl unknown
- 2007-12-03 DK DK07858987.6T patent/DK2125786T3/da active
- 2007-12-03 KR KR1020097015193A patent/KR20090092338A/ko not_active Ceased
- 2007-12-03 MX MX2009006528A patent/MX2009006528A/es active IP Right Grant
- 2007-12-03 AT AT07858987T patent/ATE502028T1/de active
- 2007-12-03 KR KR1020127009903A patent/KR20120043775A/ko not_active Ceased
- 2007-12-03 RU RU2009123347/04A patent/RU2430918C2/ru not_active IP Right Cessation
- 2007-12-03 PT PT07858987T patent/PT2125786E/pt unknown
- 2007-12-03 BR BRPI0720936-3A patent/BRPI0720936A2/pt not_active IP Right Cessation
- 2007-12-03 ES ES07858987T patent/ES2360014T3/es active Active
- 2007-12-03 NZ NZ577716A patent/NZ577716A/xx not_active IP Right Cessation
- 2007-12-03 WO PCT/IB2007/003819 patent/WO2008084299A1/en not_active Ceased
- 2007-12-03 US US12/515,612 patent/US8283471B2/en not_active Expired - Fee Related
- 2007-12-03 DE DE602007013294T patent/DE602007013294D1/de active Active
- 2007-12-18 AR ARP070105692A patent/AR064417A1/es not_active Application Discontinuation
- 2007-12-19 JP JP2007327323A patent/JP5254602B2/ja not_active Expired - Fee Related
- 2007-12-20 TW TW096148920A patent/TWI359660B/zh not_active IP Right Cessation
-
2009
- 2009-06-16 IL IL199389A patent/IL199389A/en active IP Right Review Request
- 2009-06-17 ZA ZA200904230A patent/ZA200904230B/xx unknown
-
2011
- 2011-05-17 CY CY20111100481T patent/CY1111919T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012530086A5 (enExample) | ||
| CN103159738B (zh) | 炔基桥连的杂芳香化合物及其应用 | |
| AU2012328476B2 (en) | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1 | |
| AU2014241759B2 (en) | Substituted naphthyridine and quinoline compounds as MAO inhibitors | |
| WO2013103931A1 (en) | Substituted 1-benzylindolin-2-one analogs as positive allosteric modulators of muscarinic acetylcholine m1 receptors | |
| CL2011003205A1 (es) | Compuesto 5,8-dimetil-2-[2-(1-metil-4-fenil-1h-imidazol-2-il)-etil]-[1,2,4]triazolo[1,5-a]pirazina; composicion farmaceutica; y su uso para el tratamiento de un trastorno neurodegenerativo, tales como alzheimer y demencias. | |
| JP2012510437A5 (enExample) | ||
| TR201904614T4 (en) | Novel pyrazole derivative. | |
| NZ600368A (en) | Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators | |
| NZ603230A (en) | Nitrogen containing heteroaryl compounds | |
| WO2014030716A1 (ja) | ピラゾロピリミジン化合物 | |
| JP2010520263A5 (enExample) | ||
| CA2876979A1 (en) | Substituted bicyclic alkoxy pyrazole analogs as allosteric modulators of mglur5 receptors | |
| RU2009123347A (ru) | Соль сукцинат 2-(1-метил-4-(пиридин-4-ил)-1н-пиразол-3-ил)фенокси)метил)хинолина | |
| JP2017520540A5 (enExample) | ||
| JP2020504743A (ja) | Ｎｍｄａ受容体モジュレーターおよびその使用 | |
| JP2017526659A5 (enExample) | ||
| JP2012508275A5 (enExample) | ||
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| WO2017100593A1 (en) | Thienopyrimidinone nmda receptor modulators and uses thereof | |
| WO2015080904A1 (en) | Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 | |
| AU2014368601A1 (en) | Quinazolin-THF-amines as PDE1 inhibitors | |
| WO2014179237A1 (en) | Substituted 3-benzylquinoxalin-4(3h)-one analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 | |
| JP2011516588A5 (enExample) | ||
| RU2533819C2 (ru) | Синтез и новые солевые формы (r)-5-((e)-2-(пирролидин-3-илвинил)пиримидина |